? Comparative Pathology Core The Comparative Pathology Core (CPC) is an established Shared Resource within the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine (Penn Vet), and a fully integrated Shared Resource of the Abramson Cancer Center (ACC). The main objective of the CPC is to provide skillful interpretation of lesions in animals to fulfill the needs of ACC members using animal models of disease. Among the services provided are a full-service histology, clinical laboratory services for bloodwork and cytology, immunohistochemistry, digital pathology, comprehensive mouse phenotyping, slide evaluation and interpretation, study design consultation, necropsy training, and photomicroscopy. The IHC service (immunohistochemistry) utilizes an automated platform, multiplex immunofluorescence, and in situ hybridization; the CPC has numerous in-stock optimized antibodies, as well as the ability to work-up novel antibodies for investigators. The CPC was awarded an NIH Shared Instrumentation Grant (S10) in 2018 for the Aperio VERSA scanner and eSlide Manager image analysis system. This digital scanner provides brightfield and fluorescence imaging of tissues and is fully integrated with whole slide imaging software, allowing the CPC to offer state-of-the-art quantitative analysis. Amy Durham, MS, VMD, Diplomate of the American College of Veterinary Pathologists and Associate Professor in the Department of Pathobiology at Penn Vet, developed and directs the CPC. She is a board-certified anatomic veterinary pathologist with considerable experience in animal models of cancer and has been involved in numerous collaborative research projects with members of the ACC. Enrico Radaelli, DVM, PhD, Diplomate of the European College of Veterinary Pathology, is the CPC Technical Director. He has more than a decade of experience in the pathobiology of laboratory animals used in preclinical/biomedical research with an emphasis on the phenotyping of genetically engineered mouse models. The CPC developed a fellowship program in 2018 to expand services and usage, and two additional veterinary pathologists now support the CPC mission. CPC pathologists work with multiple Research Programs, including Tumor Biology, Cancer Therapeutics, Breast Cancer, Immunobiology, and Radiobiology and Imaging. ACC members accounted for 61 of 190 investigators (32%) using the Shared Resource during the most recent reporting period (07/01/18-06/30/19). The CPC is instrumental in providing support for multiple high impact studies, including the characterization and validation of translational mouse models of glioblastoma multiforme to study the impact of epidermal growth factor receptor extracellular domain missense mutations at alanine 289 in vivo (Binder et al., Cancer Cell, 2018). Recognition and accurate interpretation of gross and histopathological lesions in animal models is essential for the success of cancer research. As the use and complexity of animal models in cancer research continues to increase, the CPC has grown with this demand, expanding the breadth and depth of its services to best serve ACC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088760
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications